Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| OKYO | PRESS-RELEASE | bullish | 6/10 | OKYO Pharma announced first patients enrolled in the Phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain (NC | Oct 6, 2026 |
| QNTM | PRESS-RELEASE | neutral | 4/10 | Quantum BioPharma announced a Study Start-Up Agreement with Thermo Fisher's PPD clinical research business to initiate i | Oct 6, 2026 |
| SYRE | PRESS-RELEASE | bearish | 6/10 | Spyre Therapeutics priced a $350M underwritten public offering of 4,117,648 shares at $85.00/share, with an underwriter | Oct 5, 2026 |
| VOR | PRESS-RELEASE | neutral | 2/10 | Vor Bio granted stock options and RSUs to 9 newly hired employees as inducement awards under Nasdaq Rule 5635(c)(4). Thi | Oct 5, 2026 |
| ALMR | PRESS-RELEASE | neutral | 2/10 | Alamar Biosciences announced the appointment of Bob Ragusa (former CEO of GRAIL and COO of Illumina) to its board of dir | Oct 5, 2026 |
| KRRO | PRESS-RELEASE | neutral | 4/10 | Korro Bio dosed the first cohort of healthy volunteers in its Phase 1/2 ANCHOR trial for KRRO-121, a GalNAc-conjugated R | Oct 5, 2026 |
| EQ | PRESS-RELEASE | neutral | 4/10 | Equillium received Australian regulatory clearance (HREC approval and TGA clearance) to begin a Phase 1 trial of EQ504, | Oct 5, 2026 |
| ORIC | PRESS-RELEASE | bullish | 6/10 | ORIC Pharmaceuticals announced a partnership with Cancer Research UK to fully fund and execute CTA-enabling studies and | Oct 5, 2026 |
| SYRE | PRESS-RELEASE | bearish | 5/10 | Spyre Therapeutics announced an underwritten public offering of common stock, with an underwriter option for an addition | Oct 5, 2026 |
| BBIO | PRESS-RELEASE | neutral | 2/10 | BridgeBio Pharma announced a nationwide education campaign to raise awareness of ATTR cardiac amyloidosis (ATTR-CM), inc | Oct 5, 2026 |
| GRML | PRESS-RELEASE | neutral | 4/10 | Greenland Mines exercised its option to acquire an additional 9.9% of AnorTech for ~US$5.3M (C$7.55M), paid in Greenland | Oct 5, 2026 |
| BCAX | PRESS-RELEASE | neutral | 2/10 | Bicara Therapeutics granted inducement stock options for 207,150 shares to two new employees under its 2026 Inducement P | Oct 5, 2026 |
| ARDX | PRESS-RELEASE | neutral | 2/10 | Ardelyx announced three abstracts will be presented at ASN Kidney Week 2026, highlighting real-world evidence for tenapa | Oct 5, 2026 |
| CBIO | PRESS-RELEASE | neutral | 4/10 | Crescent Biopharma announced FDA clearance of its IND application for CR-002, a topoisomerase inhibitor ADC targeting PD | Oct 5, 2026 |
| BBIO | PRESS-RELEASE | bullish | 7/10 | BridgeBio presented new exploratory cardiac data from the Phase 3 FORTIFY trial of BBP-418 in LGMD2I/R9 at the World Mus | Oct 5, 2026 |
| ATHE | PRESS-RELEASE | bullish | 8/10 | Alterity Therapeutics announced that its Phase 2 trial of ATH434 50 mg in Multiple System Atrophy (MSA) met its primary | Oct 5, 2026 |
| NRIX | PRESS-RELEASE | bullish | 6/10 | Nurix Therapeutics announced a two-year extension of the research term for an undisclosed oncology program under its exi | Oct 5, 2026 |
| HROW | PRESS-RELEASE | bullish | 6/10 | Harrow closed its acquisition of TYRVAYA (varenicline solution) nasal spray from Viatris for $30M in cash at closing, wi | Oct 5, 2026 |
| PBM | PRESS-RELEASE | neutral | 4/10 | Psyence BioMed's Texas subsidiary, TIRC, signed a manufacturing services agreement with DEA-registered Benuvia Operation | Oct 5, 2026 |
| ALEC | PRESS-RELEASE | bullish | 7/10 | Alector granted Genentech exclusive global rights to develop and commercialize AL050, a brain-penetrant GCase ERT for Pa | Oct 5, 2026 |
| LYB | PRESS-RELEASE | neutral | 1/10 | LyondellBasell announced it will report its Q3 results on October 30, 2026. | Oct 5, 2026 |
| PCVX | PRESS-RELEASE | bullish | 7/10 | Vaxcyte announced positive topline results from the OPUS-1 pivotal Phase 3 trial of VAX-31, its 31-valent pneumococcal c | Oct 5, 2026 |
| ALVO | PRESS-RELEASE | bullish | 7/10 | FDA approved a supplement to Alvotech's BLA for AVT02 (SIMLANDI®), enabling drug substance manufacturing in a second pro | Oct 5, 2026 |
| PCVX | PRESS-RELEASE | mixed | 8/10 | Vaxcyte announced it will host a webcast on October 5, 2026 to present topline Phase 3 data from the OPUS-1 trial of VAX | Oct 4, 2026 |
| OLMA | PRESS-RELEASE | neutral | 2/10 | Olema Oncology granted inducement stock options for 235,950 shares to six new employees at $8.27/share, vesting over fou | Oct 2, 2026 |
| IKT | PRESS-RELEASE | neutral | 2/10 | Inhibikase Therapeutics granted 128,000 non-qualified stock options to two newly-hired non-executive employees as an ind | Oct 2, 2026 |
| NTLA | PRESS-RELEASE | neutral | 2/10 | Intellia Therapeutics granted inducement stock awards to eight new employees under its 2024 Inducement Plan. This is a r | Oct 2, 2026 |
| CATX | PRESS-RELEASE | neutral | 3/10 | Perspective Therapeutics announced that data from its lapemelanotide zapixetar ([²¹²Pb]VMT01) program for metastatic mel | Oct 2, 2026 |
| BIIB | PRESS-RELEASE | bullish | 6/10 | Biogen announced positive 52-week Phase 2 data for litifilimab in cutaneous lupus erythematosus (CLE), showing continued | Oct 2, 2026 |
| INKT | PRESS-RELEASE | neutral | 4/10 | MiNK Therapeutics presented preclinical data at SITC 2026 showing agenT-797 enables tumor-cell killing in a checkpoint i | Oct 2, 2026 |